Accessibility to targeted oncology drugs in Slovenia and selected European countries

European Journal of Cancer

Volumn 44, Issue 3, 2008, Pages 408-418

  Kos, Mitja ^a   Obradovic, Marko ^a   Mrhar, Ales ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Accessibility; Cancer; Comparison; Europe; Oncology; Slovenia; Targeted oncology drugs

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; PACLITAXEL; RITUXIMAB; TRASTUZUMAB;

ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CARCINOMA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG INDICATION; DRUG UPTAKE; DRUG USE; DRUG UTILIZATION; EUROPE; FOLLICULAR LYMPHOMA; FRANCE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REMISSION; SLOVENIA; SWITZERLAND; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; EUROPE; FEMALE; HUMANS; MALE; NEOPLASMS; PHARMACOEPIDEMIOLOGY; SLOVENIA;

EID: 38749151291     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.11.020     Document Type: Article

References (10)

1. Rotea W., and Saad E.D. Targeted drugs in oncology: New names, new mechanisms, new paradigm. Am J Health-Syst Pharm 60 12 (2003) 1233-1245
2. Meropol N.J., and Schulman K.A. Cost of cancer care: issues and implications. Journal of Clinical Oncology 25 2 (2007) 180-186
3. Jönsson B., and Wilking N. A global comparison regarding patient access to cancer drugs. Annals of Oncology 18 Supplement 3 (2007) 1:78
4. The WHO Collaborating Centre for Drug Statistics Methodology. URL: http://www.whocc.no/atcddd/ (Accessed: 4th May 2007).
5. PharMIS database. Sales data for Slovenia for the period 1999-2005. MIS Consulting d.o.o., Ljubljana, Slovenia.
6. IMS MIDAS. Sales data for Austria, France, Germany, Italy, Sweden, Switzerland and UK for the period 1999-2005, IMS Health. Norwalk, USA.
7. CancerMondial. URL: http://www-dep.iarc.fr/ (Accessed: 4th May 2007).
8. Gross domestic product in purchasing power standard. Statistical Office of the Republic Slovenia. URL: http://www.stat.si/novica_prikazi.aspx?ID=787 (Accessed: 4th May 2007).
9. Eurostat. Statistical Office of the European Communities. URL: http://epp.eurostat.ec.europa.eu/ (Accessed: 23rd November 2007).
10. Kos M., Obradovic M., Mrhar A., et al. Admission of new oncological drugs to the Slovenian health care system and their accessibility to the patients. Zdrav Vestn 76 (2007) 529-538